Collegium Pharmaceutical (COLL) EBIT (2014 - 2026)

Collegium Pharmaceutical has reported EBIT for 13 years, with the latest figure at $3.7 million in Q2 2026.

• On a quarterly basis, EBIT fell 89.47% year-over-year to $3.7 million in Q2 2026; TTM through Jun 2026 was $157.4 million, a 21.35% increase from a year earlier, with the FY2025 full-year figure at $179.6 million, up 5.73% from the prior year.
• EBIT was $3.7 million for Q2 2026 at Collegium Pharmaceutical, down from $30.9 million in the prior quarter.
• The five-year high for EBIT was $62.1 million in Q3 2025, with the low at -$10.0 million in Q1 2022.
• Average EBIT over 5 years is $32.5 million, with a median of $35.0 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2023: EBIT tumbled 147.26% in 2022, then soared 424.69% in 2023.
• Over 5 years, EBIT stood at $11.8 million in 2022, then jumped by 424.69% to $61.7 million in 2023, then tumbled by 38.22% to $38.1 million in 2024, then soared by 59.42% to $60.8 million in 2025, then tumbled by 93.91% to $3.7 million in 2026.
• The last three EBIT figures came in at $3.7 million (Q2 2026), $30.9 million (Q1 2026), and $60.8 million (Q4 2025), per Business Quant data.